Proscan Rx Pharma Inc.

Theratechnologies Inc.

Koranex Capital

Serge Moffett

Phil Gold

Claudio A Cuello

Uri H Saragovi

Krishna G Peri

Pierre Du Ruisseau

Daniel Abran

Serge Mignani

Nicole Bernard

Tze Chieh Shiao

Rene Roy

Dominic Melançon

Annie Bergeron

Ram Vishwakarma

Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described. Specifically, the use of (neo)glycoconjugates as vaccine candidates and other therapeutic tools against cancers, viruses such as SARS-CoV-2, and other diseases characterized by expression of aberrant glycosylation are also described.

Neoglycoconjugates as vaccines and therapeutic tools

Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.

Antibodies against prostate specific membrane antigen

The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.

Prostate cancer diagnosis and treatment

The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.

Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus and the like are provided herein. The antagonistic peptides of the present invention can include the following formula:X-A-RYwherein 'X' is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; 'A' is L-(4,4')-biphenylalanine or D-(4,4&#x2032;)-biphenylalanine; &#x201c;R&#x201d; is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; &#x201c;Y&#x201d; is lysine; &#x201c;n&#x201d; is an integer ranging from 5 to 7; and &#x201c;m&#x201d; is an integer ranging from 0 to 2.

Antagonistic peptides of prostaglandin E2 receptor subtype EP4

A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.

Growing community of inventors

St-Laurent, Canada

Serge Moffett